RecruitingNCT03547856

A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"


Sponsor

Yan Li

Enrollment

10,000 participants

Start Date

Jul 18, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population. Information of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This trial is a large registry study tracking patients with high blood pressure who wear a 24-hour blood pressure monitor, to understand how blood pressure patterns throughout the day and night relate to health outcomes and treatment effectiveness. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with high blood pressure and are already taking blood pressure medication - You have had a 24-hour blood pressure monitoring test done with a validated device - You are willing to share your health history and recent blood test results (within 6 months) - You are willing to sign an informed consent form **You may NOT be eligible if...** - You are not currently taking any blood pressure medications - You are currently hospitalized for high blood pressure - You are unlikely to comply with study requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03547856


Related Trials